DÄ internationalArchiveReferences
References

Review article

QTc Prolongation by Psychotropic Drugs and the Risk of Torsade de Pointes

Dtsch Arztebl Int 2011; 108(41): 687-93. DOI: 10.3238/arztebl.2011.0687

Wenzel-Seifert, K; Wittmann, M; Haen, E

1. Altmann D, Eggmann U, Ammann P: Medikamentös induzierte Verlängerung des QT-Intervalls. [Drug induced QT prolongation]. Wien Klin Wochenschr 2008; 120: 128–35. CrossRef MEDLINE
2.Haverkamp H, Deuschle M: Antipsychotikainduzierte QT-Verlängerung. [Antipsychotica-induced QT-prolongation]. Nervenarzt 2006; 77: 276–88. CrossRef MEDLINE
3. Gupta A, Lawrence AT, Krishnan K, Kavinsky CJ, Trohmann RG: Current concepts in the mechanisms and management of drug-induced QT prolongation and torsade de pointes. Am Heart J 2007; 153: 891–9. CrossRef MEDLINE
4.Harrigan EP, Miceli JJ, Anziano R, Watsky E, Reeves KR, Cutler NR, et al.: A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition. J Clin Psychopharmacology 2004; 24: 62–9. CrossRef MEDLINE
5. Stöllberger C, Huber JO, Finsterer J: Antipsychotic drugs and QT prolongation. Int Clin Psychopharmacology 2005; 20: 243–51. CrossRef MEDLINE
6. Reilly JG, Ayes SA, Ferrier IN: QTc interval abnormalities and psychotropic drug therapy in psychiatric patients. Lancet 2000; 335: 1048–52. CrossRef MEDLINE
7. van Noord C, Straus S, Sturkenboom M, Hofman A, Aarnoudse AJ, Bagnardi V, et al.: Psychotropic drugs associated with corrected QT interval prolongation. J Clin Psychopharmacology 2009; 29: 9–15. CrossRef MEDLINE
8. Astrom-Lilja C, Odeberg JM, Ekman E, Hägg S: Drug-induced torsades de pointes: a review of the Swedish pharmacovigilance database. Pharmacoepidemiology and Drug Safety 2008; 17: 587–92. CrossRef MEDLINE
9. Woosley RL, Anthony M, Armstrong EP, Assenzo JR for Arizona CERT – QT Drug Lists by Risk Groups: accessed 30. 8. 2010.
10.Goodnick PJ, Jerry J, Parra F: Psychotropic drugs and the ECG: focus on the QTc interval. Expert Opin Pharmacother 2002; 3: 479–98. CrossRef MEDLINE
11. Lohse MJ, Müller-Oerlinghausen B: Psychopharmaka. In: Schwabe U, Paffrath D (eds.): Arzneiverordnungs-Report 2010: Aktuelle Daten, Kosten, Trends und Kommentare. Berlin 2010: 497–841. CrossRef
12. Ozeki Y, Fujii K, Kurimoto N, Yamada N, Okawa M, Aoki T, et al.: QTc prolongation and antipsychotic medications in a sample of 1017 patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2010; 34: 401–5. CrossRef MEDLINE
13. Haddad PM, Anderson IM: Antipsychotic-related QTc prolongation, torsade de pointes and sudden death. Drugs 2002; 62: 1649–71. CrossRef MEDLINE
14. Alvarez PA, Pahissa J: QT alterations in psychopharmacology: proven candidates and suspects. Curr Drug Saf 2010; 5: 97–104. CrossRef MEDLINE
15. Sharma ND, Rosmann HS, Padhi ID, Tisdale JE: Torsades de pointes associated with intravenous haloperidol in critically ill patients. Am J Cardiol 1998; 81: 238–40. CrossRef MEDLINE
16. Vieweg WV, Wood MA, Fernandez A, Beatty-Brooks M, Hasnain M, Pandurangi AK: Proarrhythmic risk with antipsychotic and antidepressant drugs: implications in the elderly. Drugs Aging 2009; 26: 997–1012. CrossRef MEDLINE
17. Sala M, Vicentini A, Brambilla P, Montomoli C, Jogia JR, Caverzasi E, et al.: QT interval prolongation related to psychoactive drug treatment: a comparison of monotherapy versus polytherapy. Ann Gen Psychiatry 2005; 4(1): 1. doi: 10.1186/744–859X-4–1. CrossRef MEDLINE
18. Vieweg WV, Wood MA: Tricyclic antidepressants, QT interval prolongation, and torsade de pointes. Psychosomatics 2004; 45: 371–7. CrossRef MEDLINE
19. Poluzzi E, Raschi E, Moretti U, De Ponti F: Drug-induced torsades de pointes: data mining of the public version of the FDA Adverse Event Reporting System (AERS). Pharmacoepidemiol Drug Saf 2009; 18: 512–8. CrossRef MEDLINE
20. Wenzel-Seifert K, Wittmann M, Haen E: Torsade de Pointes episodes under treatment with selective serotonin reuptake inhibitors. Pharmacopsychiatry 2010; 43: 279–81. CrossRef MEDLINE
21. de Gregorio C, Morabito G, Cerrito M, Dattilo G, Oreto G: Citalopram-induced long QT syndrome and torsade de pointes: Role for committant therapies and illnesses. Int J Cardiol 2011; 148: 226–8. CrossRef MEDLINE
22. Wedam EF, Bigelow GE, Johnson RE, Nuzzo PA, Haigney MC: QT-interval effects of methadone, levomethadyl, and buprenorphine in a randomized trial. Arch Intern Med 2007; 167: 2469–75. CrossRef MEDLINE
23. DePonti F, Poluzzi E, Montanaro N: Organising evidence on QT prolongation and occurrence of Torsades de Pointes with non-anti-arrhythmic drugs: a call for consensus. Eur J Clin Pharmacol 2001; 57: 185–209. CrossRef MEDLINE
24. Haverkamp W, Haverkamp F, Breithard G: Medikamenteninduzierte QT-Verlängerung und Torsade de pointes. Ein multidisziplinäres Problem. Dtsch Arztebl 2002; 99: A 1872–9. VOLLTEXT
25. Chong SA, Mythily, Lum A, Goh HY, Chan YH: Prolonged QTc intervals in medicated patients with schizophrenia. Hum Psychopharmacol 2003; 18: 647–9. CrossRef MEDLINE
e1.FDA: Information for Healthcare Professionals: Haloperidol. FDA ALERT 9/2007.
e2. Arzneimittelkommission der Deutschen Ärzteschaft: Information über die Änderung der bisher empfohlenen Applikationswege von Haldol®-Janssen-Injektionslösung. AkdÄ Drug Safety Mail 2010–098 5th May 2010.
e3. Llerena A, Berecz R, Dorado P, de la Rubia A: QTc interval, CYP2D6 and CYP2C9 genotypes and risperidone plasma concentrations. J Psychopharmacol 2004; 18: 189–93. MEDLINE
e4. Janicak PG, Winans EA: Paliperidone ER: a review of the clinical trial data. Neuropsychiatr Dis Treat 2007; 3: 869–97. MEDLINE
e5. Lieberman JA, Strout TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al.: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353: 1209–23. MEDLINE
e6. Warner B, Hoffmann P: Investigation of the potential of clozapine to cause torsade de pointes. Adverse Drug React Toxicol Rev 2002; 21: 189–203. MEDLINE
e7. Kang UG, Kwon JS, Ahn YM, Chung SJ, Ha JH, Koo YJ, et al.: Electrocardiographic abnormalities in patients treated with clozapine. J Clin Psychiatry 2000; 61: 441–6. MEDLINE
e8. Llorca PM, Pere JJ: Leponex®, 10 ans après – Une revue clinique [Leponex, 10 years after—a clinical review] [Article in French]. Encephale 2004; 30: 474–91. MEDLINE
e9. Isbister GK, Balit CR, MacLoed D, Duffull SB: Amisulpride overdose is frequently associated with QT prolongation and torsades de pointes. J Clin Psychopharmacol 2010; 30: 391–5. MEDLINE
e10. Brugisser M, Bravo A, Bodner M: Medikamenten-assoziiertes Long-QT-Syndrom [Medication associated long QT syndrome]. Praxis 2009; 98: 1409–15. MEDLINE
e11. Goodnick PJ, Jerry JM: Aripiprazole: profile on efficacy and safety. Expert Opin Pharmacother 2002; 3: 1773–81. MEDLINE
e12. Huang BH, Hsia CP, Chen CY: Sulpiride induced torsade de pointes. Int J Cardiol 2007; 118: e100–2. MEDLINE
e13. Chang JH, Weng TI, Fang CC: Long QT syndrome and torsades de pointes induced by acute sulpiride poisoning. Am J Emerg Med 2009; 27: 1016. e1–e3 MEDLINE
e14. Sala M, Vicentini A, Brambilla P, Montomoli C, Jogia JR, Caverzasi E, et al.: QT interval prolongation related to psychoactive drug treatment: a comparison of monotherapy versus polytherapy. Ann Gen Psychiatry 2005; 4: 1–6. MEDLINE
e15. Dattilo PB, Nordin C: Prolonged QT associated with an overdose of trazodone. J Clin Psychiatry 2007; 68: 1309–10. CrossRef MEDLINE
e16. Levenson JL: Prolonged QT interval after trazodone overdose. Am J Psychiatry 1999; 156: 969–70. MEDLINE
e17. Hsu CH, Liu PY, Chen JH, Yeh TL, Tsai HY, Lin LJ: Electrocardiographic abnormalities as predictors for over-range lithium levels. Cardiology 2005; 103: 101–6. MEDLINE
e18. Kanjanauthai S, Kanluen T, Charreonthaitawee P: Citalopram induced torsade de pointes, a rare life threatening side effect. Intl J Cardiol 2008; 131: e33–e34. MEDLINE
e19. Meuleman C, Jourdain P, Bellorini M, Sadeg N, Loiret J, Guillard N, et al.: Citalopram et torsades de pointes : A propos d’un cas. [Citalopram and Torsades de Pointes: A case report]. Archives des maladies du coeur et des vaisseaux 2001; 94: 1021–4. MEDLINE
e20. Tarabar AF, Hoffman RS, Nelson L: Citalopram overdose: late presentation of torsades de pointes (TdP) with cardiac arrest. J Med Toxicol 2008; 4: 101–5. CrossRef MEDLINE
e21. Dorsey ST, Biblo LA: Prolonged QT interval and torsades de pointes caused by the combination of fluconazole and amitriptyline. Am J Emerg Med 2000; 18: 227–9. CrossRef MEDLINE
e22. Lentini S, Rao ML, Schröder R, Lüderitz B, Bauriedel G: QT-Verlängerung und Torsade de pointes-Tachykardie bei Therapie mit Maprotilin. Differenzialdiagnostische und -therapeutische Aspekte. [QT prolongation and torsade de pointes tachycardia during therapy with maprotiline. Differential diagnostic and therapeutic aspects]. Dtsch Med Wochenschr 2001; 49: 1396–400. MEDLINE
e23. Davison ET: Amitriptyline-induced Torsade de Pointes. Successful therapy with atrial pacing. J Electrocardiol 1985; 18: 299–301. CrossRef MEDLINE
e24. Alter P, Tontsch D, Grimm W: Doxepin-induced torsade de pointes tachycardia. Ann Intern Med 2001; 135: 384–5. MEDLINE
e25. Tzivoni D, Keren A, Cohen AM, Loebel H, Zahavi I, Chenzbraun A, et al.: Magnesium therapy for torsades de pointes. Am J Cardiol 1984; 53: 528–30. MEDLINE
e26. Reddy S, Hui D, El Osta B, de la Cruz M, Walker P, Palmer JL, et al.: The effect of oral methadone on the QTc interval in advanced cancer patients: a prospective pilot study. J Palliat Med 2010; 13: 33–8. MEDLINE
e27. George S, Moreira K, Fapohunda M: Methadone and the heart: what the clinician needs to know. Curr Drug Abuse Rev 2008; 1: 297–302. MEDLINE
e28. Justo D, Gal-Oz A, Paran Y, Goldin Y, Zeltser D: Methadone-associated Torsades de Pointes (polymorphic ventricular tachycardia) in opioid-dependent patients. Addiction 2006; 101: 1333–8. MEDLINE
e29. Krähenbühl S, Sauter B, Kupferschmidt H, Krause M, Wyss PA, Meier PJ: Case report: reversible QT prolongation with torsades de pointes in a patient with pimozide intoxication. Am J Med Sci 1995; 309: 315–6. MEDLINE
e30. Hoehns JD, Stanford RH, Geraets DR, Skelly KS, Lee HC, Gaul BL: Torsades de pointes associated with chlorpromazine: case report and review of associated ventricular arrhythmias. Pharmacotherapy 2001; 21: 871–83. MEDLINE
e31. Ochiai H, Kashiwagi M, Usui T, Oyama Y, Tokita Y, Ishikawa T: [Torsade de Pointes with T wave alternans in a patient receiving moderate dose of chlorpromazine: report of a case] Japanese. Kokyu To Junkan 1990; 38: 819–22. MEDLINE
e32. Hui WK, Mitchell LB, Kavanagh KM, Gillis AM, Wyse DG, Manyari DE, et al.: Melperone: electrophysiologic and antiarrhythmic activity in humans. J Cardiovasc Pharmacol 1990; 15: 144–9. MEDLINE
e33. Kondou N, Hiasa Y, Kishi K, Fujinaga H, Ohishi Y, Ohtani R, et al.: [A case of life-threatening ventricular arrhythmias probably due to psychotropic drugs]. [Article in Japanese]. Kokyu To Junkan 1993; 41: 1117–20. MEDLINE
e34. Jo SH, Hong HK, Chong SH, Lee HS, Choe H: H1 antihistamine drug promethazine directly blocks hERG K+ channel. Pharmacol Res 2009; 60: 429–37. MEDLINE
e35. Bont L, Bosker HA, Brus F, Yska JP, Bosch FH: Torsade de pointes after pipamperone intoxication. Pharm World Sci 1998; 20: 137. CrossRef MEDLINE
e36. Vieweg WV, Schneider RK, Wood MA: Torsade de pointes in a patient with complex medical and psychiatric conditions receiving low-dose quetiapine. Acta Psychiatr Scand 2005; 112: 318–20. CrossRef MEDLINE
e37. Gajwani P, Pozuelo L, Tesar GE: QT interval prolongation associated with quetiapine (Seroquel) overdose. Psychosomatics 2000; 41: 63–5. MEDLINE
e38. Blaschke D, Parwani AS, Huemer M, Rolf S, Boldt LH, Dietz R, et al.: Torsade de pointes during combined treatment with risperidone and citalopram. Pharmacopsychiatry 2007; 40: 294–5. MEDLINE
e39. Chung AKK, Chua SE: Torsade de pointes with low-dose amisulpride: a case report. J Psychopharmacol 2010; 24: 433–5. CrossRef MEDLINE
e40. Lin YC, Su HK, Ouyang WC, Lane HY: Zotepine-induced QTc prolongation. J Clin Psychopharmacol 2008; 28: 576–8. MEDLINE
e41. Cohn JB, Wilcox CS, Goodman LI: Antidepressant efficacy and cardiac safety of trimipramine in patients with mild heart disease. Clin Ther 1992; 15: 115–26.
e42. Züchner H: QT-Verlängerung und Torsade de pointes-Tachykardie bei Therapie mit Maprotilin. [QT prolongation and torsade de pointes-tachycardia in therapy with maprotiline]. Dtsch Med Wochenschr 2002; 127: 983–4. CrossRef MEDLINE
e43. Möller HJ, Volz HP, Reimann IW, Stoll KD: Opipramol for the treatment of generalized anxiety disorder: a placebo-controlled trial including an alprazolam-treated group. J Clin Psychopharmacol 2001; 21: 59–65. CrossRef MEDLINE
e44. Letsas K, Korantzopoulos P, Pappas L, Evangelou D, Efremidis M, Kardaras F: QT interval prolongation associated with venlafaxine administration. Int J Cardiol 2006; 109: 116–7. MEDLINE
e45. Bosse GM, Spiller HA, Collins AM: A fatal case of venlafaxine overdose. J Med Toxicol 2008; 4: 18–20. MEDLINE
e46. Fleishaker JC, Francom SF, Herman BD, Knuth DW, Azie NE: Lack of effect of reboxetine on cardiac repolarization. Clin Pharmacol Ther 2001; 70: 261–9. MEDLINE
e47. Norman TR, Olver JS: Duloxetine in the treatment of generalized anxiety disorder. Neuropsychiatr Dis Treat 2008; 4: 1169–80. MEDLINE
e48. Raskin J, Wiltse CG, Dinkel JJ, Walker DJ, Desaiah D, Katona C: Safety and tolerability of duloxetine at 60 mg once daily in elderly patients with major depressive disorder. J Clin Psychopharmacol 2008; 28: 32–8. CrossRef MEDLINE
e49. Wernicke J, Lledó A, Raskin J, Kajdasz DK, Wang F: An evaluation of the cardiovascular safety profile of duloxetine: findings from 42 placebo-controlled studies. Drug Saf 2007; 30: 437–55. MEDLINE
e50. Zhang L, Chappell J, Gonzales CR, Small D, Knadler MP, Callaghan JT, et al.: QT effects of duloxetine at supratherapeutic doses: a placebo and positive controlled study. J Cardiovasc Pharmacol 2007; 49: 143–53. MEDLINE
e51. Ansermont N, Albayrak O, Schläpfer J, Crettol S, Croquette-Krokar M, Bourquin M, et al.: Substitution of (R,S)-methadone by (R)-methadone: Impact on QTc interval. Arch Intern Med 2010; 170: 529–36. MEDLINE
e52. Sing K, Erickson T, Amitai Y, Hryhorczuk D: Chloral hydrate toxicity from oral and intravenous administration. J Toxicol Clin Toxicol 1996; 34: 101–6. MEDLINE
e53. Hill SL, El-Khayat RH, Sandilands EA, Thomas SH: Electrocardiographic effects of methylphenidate overdose. Clin Toxicol (Phila) 2010; 48: 342–6. MEDLINE
e54.Negrao BL, Crafford D, Viljoen M: The effect of sympathomimetic medication on cardiovascular functioning of children with attention-deficit/hyperactivity disorder. Cardiovasc J Afr 2009; 20: 296–9. MEDLINE
e55. Simpson D, Plosker GL: Spotlight on atomoxetine in adults with attention-deficit hyperactivity disorder. CNS Drugs 2004; 18: 397–401. CrossRef MEDLINE
e56. Wernicke JF, Faries D, Girod D, Brown J, Gao H, Kelsey D, et al.: Cardiovascular effects of atomoxetine in children, adolescents, and adults. Drug Saf 2003; 26: 729–40. MEDLINE
e57. Ciszowski K, Szpak D, Jenner B: The influence of carbamazepine plasma level on blood pressure and some ECG parameters in patients with acute intoxication. Przegl Lek 2007; 64: 248–51. MEDLINE
e58. Kwon S, Lee S, Hyun M, et al.: The potential for QT prolongation by antiepileptic drugs in children. Pediatr Neurol 2004; 30: 99–101. MEDLINE
e59. Saetre E, Abdelnoor M, Amlie J, Tossebro M, Perucca E, Taubøll E, et al.: Cardiac function and antiepileptic drug treatment in the elderly: a comparison between lamotrigine and sustained-release carbamazepine. Epilepsia 2009; 50: 1841–9. MEDLINE
e60. Kurt E, Emul M, Ozbulut O, Guler O, Erdur F, Sağlam H, et al.: Is valproate promising in cardiac fatal arrhythmias? Comparison of P- and Q-wave dispersion in bipolar affective patients on valproate or lithium-valproate maintenance therapy with healthy controls. J Psychopharmacol 2009; 23: 328–33. MEDLINE
e61. Dixon R, Job S, Oliver R, Tompson D, Wright JG, Maltby K, et al.: Lamotrigine does not prolong QTc in a thorough QT/QTc study in healthy subjects. Br J Clin Pharmacol 2008; 66: 396–404. MEDLINE

Info

Figures and tables

Authors

Authors